Bank of America Spends Over $250 Million Annually on GLP-1 Weight Loss Drugs

2026-08-06

The BareStory

Bank of America is spending more than $250 million annually to provide GLP-1 weight loss medications to its workforce. According to company figures, this spending has risen from zero dollars roughly four to five years ago and now represents about 13% of the bank's total healthcare budget, which exceeds $2 billion annually for approximately 211,000 employees.

Bank of America CEO Brian Moynihan stated on Wednesday, August 5, 2026, that the rising cost is a worthwhile investment. Moynihan cited potential near- and long-term health benefits for employees, including weight loss and fewer cardiovascular issues. He acknowledged that some employees may leave the company before long-term savings are realized, but emphasized the value of the benefit. Moynihan also noted that the bank pairs drug access with lifestyle health coaching and is leveraging its size to negotiate lower prices from drugmakers and pharmacy benefit managers.

According to the International Foundation of Employee Benefit Plans, high costs have prompted many self-insured companies and public employers to drop or restrict coverage. A July survey by the organization showed that only about 36% of employers covered GLP-1s for both diabetes and weight loss in 2026, a figure unchanged from 2025. The survey also reported that these drugs accounted for 11.4% of annual claims in 2026, up from 6.9% in 2023.

To address cost concerns, obesity drugmakers Eli Lilly and Novo Nordisk have been pushing to increase employer coverage, according to company statements. As part of these efforts, Eli Lilly launched an initiative in March offering employers a discounted price of $449 per month for a multi-dose form of Zepbound, according to the manufacturer's program details.

Left Perspective

Shielding Workers from Health Crises
Challenging Extractive Pharmaceutical Pricing
Exposing the Divide in Corporate Care

Right Perspective

Maximizing Human Capital Returns
Leveraging Scale to Discipline Markets
Guarding Against Structural Cost Escalation

Left Perspective

• Shielding Workers from Health Crises Prioritizing human dignity and comprehensive well-being demands that employers absorb the rising costs of life-altering medical treatments like GLP-1s. Bank of America's commitment of over $250 million annually—representing 13% of its $2 billion healthcare budget—demonstrates that protecting employee health must transcend short-term profit concerns. This investment, which covers potential near- and long-term physical benefits such as weight loss and fewer cardiovascular issues, validates healthcare as a fundamental pillar of worker security.

• Challenging Extractive Pharmaceutical Pricing Systemic equity is threatened when monopolistic drug manufacturers drive corporate healthcare costs from zero to 13% of total budgets in under five years. The immense financial pressure that forces other self-insured employers—leaving only 36% offering GLP-1 coverage in 2026—to drop these benefits highlights how predatory pricing exploits the vulnerable. While Eli Lilly's $449 monthly discount for Zepbound offers minor relief, true systemic health equity cannot be achieved when access to life-saving medicine relies on corporate benevolence and backroom negotiation leverage.

• Exposing the Divide in Corporate Care Relying on employer-sponsored insurance creates a deeply unequal system where critical healthcare is restricted to those working for massive financial institutions. While Bank of America uses its scale to negotiate lower prices for its 211,000 employees, smaller enterprises and public employers are squeezed out, frozen at a stagnant 36% coverage rate. This disparity risks creating a two-tiered health landscape where access to breakthrough obesity treatments is a luxury tied strictly to elite employment rather than a universal right.

Right Perspective

• Maximizing Human Capital Returns Strategic realism dictates that a healthy workforce is a highly productive and competitive corporate asset. Allocating $250 million of a $2 billion budget toward GLP-1 treatments is a calculated investment in mitigating long-term liabilities like chronic cardiovascular issues and absenteeism. Even if some employees depart before the full savings materialize, the upfront capital expenditure secures a healthier, high-performing workforce that drives superior operational output and long-term institutional stability.

• Leveraging Scale to Discipline Markets Market efficiency is best achieved when massive private enterprises use their purchasing power to negotiate directly with drugmakers and pharmacy benefit managers. Rather than relying on state-mandated price controls, Bank of America utilizes its scale of 211,000 employees to secure lower rates, while drugmakers like Eli Lilly respond to market dynamics by offering discounted $449 monthly rates for Zepbound to incentivize coverage. This competitive interaction demonstrates that private sector scaling and active negotiation are the most effective tools to drive down healthcare delivery costs.

• Guarding Against Structural Cost Escalation Maintaining long-term fiscal discipline requires companies to carefully balance benefit expansion against structural budget inflation. The rapid rise of GLP-1 claims from 6.9% in 2023 to 11.4% in 2026 across the wider market represents an unsustainable trajectory for many self-insured organizations. While the bank pairs drug access with mandatory lifestyle health coaching to optimize treatment efficacy, unconstrained healthcare spending threatens systemic corporate stability, explaining why many employers must restrict coverage to preserve financial health.

How it may affect me

As a U.S. reader:

• If you are employed by a massive corporation, you are more likely to retain coverage for weight-loss medications paired with lifestyle coaching, whereas employees at smaller firms or public institutions face a high probability of having these benefits restricted or completely dropped.

• In the long term, workers with employer-sponsored coverage may benefit from reduced cardiovascular risks and weight loss, while those working for companies that do not cover GLP-1s could face a growing disparity in accessing breakthrough healthcare treatments.

• You may find your employer pushing to negotiate lower prices directly with drug manufacturers and pharmacy benefit managers, or utilizing manufacturer discount initiatives like Eli Lilly's multi-dose program to offset rising costs.

• As GLP-1 claims consume a larger portion of annual corporate healthcare claims, self-insured employers may restrict coverage or adjust benefit packages to prevent unsustainable structural budget inflation.

Bank of America Spends Over $250 Million Annually on GLP-1 Weight Loss Drugs

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at